05/29/2026
📢 BREAKING: The has approved datopotamab deruxtecan (Dato-DXd) for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, expanding treatment options in a setting with significant unmet need.
📊 The approval follows findings from TROPION-Breast02 demonstrating improvements in PFS and OS compared vs standard chemotherapy.
🔗 Read more: https://hubs.li/Q04hDZc20
